These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

780 related articles for article (PubMed ID: 27186364)

  • 1. Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives.
    Seino Y; Kuwata H; Yabe D
    J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):102-9. PubMed ID: 27186364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incretins: their physiology and application in the treatment of diabetes mellitus.
    Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
    Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
    Garber AJ
    Am J Manag Care; 2010 Aug; 16(7 Suppl):S187-94. PubMed ID: 20809667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.
    Yang CT; Yang CY; Ou HT; Kuo S
    Cardiovasc Diabetol; 2020 Jun; 19(1):83. PubMed ID: 32534570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy.
    Barkmeier AJ; Herrin J; Swarna KS; Deng Y; Polley EC; Umpierrez GE; Galindo RJ; Ross JS; Mickelson MM; McCoy RG
    Ophthalmol Retina; 2024 Oct; 8(10):943-952. PubMed ID: 38735641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S20-7. PubMed ID: 20824236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.
    Verspohl EJ
    Pharmacol Ther; 2009 Oct; 124(1):113-38. PubMed ID: 19545590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Management of type 2 diabetes: new or previous agents, how to choose?].
    Halimi S
    Presse Med; 2013 May; 42(5):861-70. PubMed ID: 23643613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review.
    Chai S; Niu Y; Liu F; Wu S; Yang Z; Sun F
    J Diabetes Res; 2024; 2024():8145388. PubMed ID: 39072050
    [No Abstract]   [Full Text] [Related]  

  • 11. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Nauck M
    Diabetes Obes Metab; 2016 Mar; 18(3):203-16. PubMed ID: 26489970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
    Russell S
    Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review.
    Bihan H; Ng WL; Magliano DJ; Shaw JE
    Diabetes Res Clin Pract; 2016 Nov; 121():27-34. PubMed ID: 27622682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Severe Hypoglycemia With Newer Second-line Glucose-lowering Medications in Older Adults With Type 2 Diabetes Stratified by Known Indicators of Hypoglycemia Risk.
    Htoo PT; Paik JM; Alt E; Kim DH; Wexler DJ; Kim SC; Patorno E
    J Gerontol A Biol Sci Med Sci; 2023 Dec; 78(12):2426-2434. PubMed ID: 36866496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis.
    Mishriky BM; Cummings DM; Powell JR; Sewell KA; Tanenberg RJ
    Diabetes Metab; 2019 Apr; 45(2):102-109. PubMed ID: 30243806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose-lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase-4 inhibition.
    Ahrén B
    J Diabetes Investig; 2021 Jul; 12(7):1128-1135. PubMed ID: 33949781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of dipeptidyl peptidase-4 inhibitors to insulin treatment in type 2 diabetes patients: A meta-analysis.
    Yang W; Cai X; Gao X; Chen Y; Chen L; Ji L
    J Diabetes Investig; 2018 Jul; 9(4):813-821. PubMed ID: 29047219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
    Østoft SH
    Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of incretin based therapies: clinical trial data.
    White J
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S30-40. PubMed ID: 19801363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.